Legal & General Group PLC C4 Therapeutics, Inc. Transaction History

Legal & General Group PLC

$470 Billion
Q3 2024

A detailed history of Legal & General Group PLC transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 5,063 shares of CCCC stock, worth $21,821. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,063

Previous 5,063 -0.0%

Holding current value

$21,821

Previous $28,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$4.05 - $8.1 $20,505 - $41,010	5,063 New	5,063 $23,000
Q1 2023 May 15, 2023	SELL	$3.1 - $9.02 $24,316 - $70,752	-7,844 Reduced 58.38%	5,591 $17,000
Q4 2022 Feb 14, 2023	BUY	$5.42 - $10.24 $5,810 - $10,977	1,072 Added 8.67%	13,435 $79,000
Q3 2022 Nov 14, 2022	BUY	$8.03 - $12.77 $8,166 - $12,987	1,017 Added 8.96%	12,363 $109,000
Q2 2022 Aug 22, 2022	BUY	$5.06 - $26.46 $19,000 - $99,357	3,755 Added 49.47%	11,346 $86,000
Q1 2022 May 16, 2022	SELL	$19.99 - $33.23 $479 - $797	-24 Reduced 0.32%	7,591 $185,000
Q4 2021 Feb 14, 2022	BUY	$29.39 - $46.86 $15,400 - $24,554	524 Added 7.39%	7,615 $245,000
Q3 2021 Nov 15, 2021	BUY	$35.91 - $50.5 $90,493 - $127,260	2,520 Added 55.13%	7,091 $317,000
Q2 2021 Aug 12, 2021	BUY	$30.39 - $42.18 $105,666 - $146,659	3,477 Added 317.82%	4,571 $173,000
Q1 2021 May 17, 2021	SELL	$31.96 - $46.5 $1,406 - $2,046	-44 Reduced 3.87%	1,094 $40,000
Q4 2020 Feb 12, 2021	BUY	$22.8 - $37.05 $25,946 - $42,162	1,138 New	1,138 $38,000

Others Institutions Holding CCCC

# of Institutions

130

Shares Held

63.5M

Call Options Held

670K

Put Options Held

54.8K

View Full List

About C4 Therapeutics, Inc.

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $211M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

More about CCCC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Account

Legal & General Group PLC C4 Therapeutics, Inc. Transaction History